Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalnex Solutio. Regulatory News (CLX)

Share Price Information for Calnex Solutio. (CLX)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
67.00
Ask:
70.00
Spread: 3.00 (4.478%)
Market Cap: £60.33m
CLX Live PriceLast checked at - London Stock Exchange

Intraday Calnex Solutio. Share Chart

Offer Update

7 Jun 2007 13:25

Stornoway Limited07 June 2007 Stornoway has received irrevocable undertakings to vote in favour of theAcquisition, the Scheme and the resolutions to be proposed at the EGM (includingthe Rule 16 Resolution) in respect of the entire beneficial holding of TownsleyFamily Investments Limited amounting to 701,030 Calyx Shares, representing 1.01per cent. of the existing issued share capital of Calyx. The irrevocable undertaking will cease to be binding if Stornoway announces thatit will not proceed to make the Acquisition, or the Scheme Document has not beenposted by the twenty-eighth day after the announcement of a firm intention tomake the Acquisition made by Stornoway on 25 May 2007 (or such later date asStornoway and Calyx may agree, with the consent of the Panel), or the Schemedoes not become effective by 30 September 2007 (or such later date as Stornowayand Calyx may, with the consent of the Panel, agree and the High Court mayallow), or the Scheme fails to become effective or is withdrawn, or if a highercompeting offer for Calyx is announced which is at least 10 per cent. higherthan 101 pence per Calyx Share. As a consequence of receiving this irrevocable undertaking: • Stornoway has received irrevocable undertakings to vote,or procure a vote, in favour of the Scheme in respect of a total of 23,086,596Calyx Shares representing, in aggregate, 100.00 per cent. of the existing issuedshare capital of Calyx entitled to vote at the Court Meeting for Stornoway ClassShareholders. • Stornoway has received irrevocable undertakings or lettersof intent to vote, or procure a vote, in favour of the Scheme in respect of atotal of 21,383,823 Calyx Shares representing, in aggregate, 46.05 per cent. ofthe existing issued share capital of Calyx entitled to vote at the Court Meetingfor Calyx Shareholders other than Stornoway Class Shareholders. • Stornoway has received irrevocable undertakings or lettersof intent to vote, or procure a vote, in favour of the resolutions to beproposed at the EGM (other than the Rule 16 Resolution) in respect of a total of44,470,419 Calyx Shares representing, in aggregate, 63.96 per cent. of theexisting issued share capital of Calyx entitled to vote on those resolutions. • Stornoway has received irrevocable undertakings or lettersof intent to vote, or procure a vote, in favour of the Rule 16 Resolution at theEGM in respect of a total of 24,298,681 Calyx Shares representing, in aggregate,49.23 per cent. of the existing issued share capital of Calyx held by theIndependent Shareholders, who are the only Calyx Shareholders entitled to voteon the Rule 16 Resolution. For the purpose of this announcement, the existing issued share capital of Calyxis based upon the 69,526,914 Calyx Shares in issue as at 30 May 2007. Unless otherwise defined terms used in this announcement have the same meaningas in the announcement of a firm intention to make the Acquisition made byStornoway on 25 May 2007. The directors of Stornoway, Stornoway I, Clayfox Timid and Clayfox Gilttop,acting in their capacity as such, the directors of Alchemy Partners (Guernsey),and the Management Team (together the "Responsible Parties"), acceptresponsibility for the information contained in this announcement. To the bestof the knowledge and belief of the Responsible Parties (who have taken allreasonable care to ensure that such is the case), the information contained inthis announcement for which they accept responsibility is in accordance with thefacts and does not omit anything likely to affect the import of suchinformation. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th May 20237:00 amRNSNotice of Results and Investor Presentation
14th Apr 20236:03 pmRNSPDMR Dealings
14th Apr 20233:24 pmRNSDirector Dealing
15th Mar 20231:15 pmRNSDirector Dealings
14th Mar 20234:00 pmRNSPDMR Dealings
7th Mar 20239:05 amRNSSecond Price Monitoring Extn
7th Mar 20239:00 amRNSPrice Monitoring Extension
7th Mar 20237:00 amRNSTrading Update
15th Feb 202310:59 amRNSPDMR Dealings
19th Jan 20239:56 amRNSPDMR Dealings
17th Jan 20239:56 amRNSDirector / PDMR Dealings
17th Jan 20239:52 amRNSHolding(s) in Company
17th Jan 20237:00 amRNSBoard Changes
13th Jan 20234:00 pmRNSDirector/PDMR Dealing
13th Dec 20222:15 pmRNSDirector / PDMR Dealings
22nd Nov 20227:00 amRNSInterim Results
21st Nov 20225:43 pmRNSDirector / PDMR Dealings
27th Oct 20227:00 amRNSNotice of Results and Investor Presentation
14th Oct 20223:53 pmRNSDirector/PDMR Shareholding
12th Oct 20221:29 pmRNSDirector / PDMR Dealings
15th Sep 20227:30 amRNSDirector/PDMR Dealing
17th Aug 20225:26 pmRNSResult of AGM
17th Aug 20227:00 amRNSAGM Statement
15th Aug 202210:26 amRNSDirector / PDMR Dealings
26th Jul 20223:33 pmRNSDirector / PDMR Shareholding
18th Jul 20227:00 amRNSNotice of AGM
14th Jul 20225:49 pmRNSDirector/PDMR Dealings
8th Jul 20226:01 pmRNSDirector / PDMR dealings
15th Jun 20227:00 amRNSExercise of Options
14th Jun 20227:00 amRNSBoard Update
6th Jun 20221:30 pmRNSDirector Dealing
24th May 20227:00 amRNSFY22 Final Results
6th May 20227:00 amRNSNotice of Investor Presentation
26th Apr 20229:13 amRNSAward of Options
22nd Apr 202210:50 amRNSHolding(s) in Company
21st Apr 20223:37 pmRNSPDMR Dealing
21st Apr 20227:00 amRNSCalnex receives two Queen’s awards for Enterprise
12th Apr 20227:00 amRNSAcquisition of iTrinegy and Update on Trading
1st Mar 20227:00 amRNSTrading Update
25th Jan 202210:00 amRNSDirector Dealing
11th Jan 20227:00 amRNSBoard Appointments
29th Nov 20212:00 pmRNSPrice Monitoring Extension
26th Nov 20219:55 amRNSHolding(s) in Company
23rd Nov 20214:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20214:35 pmRNSPrice Monitoring Extension
23rd Nov 20212:06 pmRNSSecond Price Monitoring Extn
23rd Nov 20212:00 pmRNSPrice Monitoring Extension
23rd Nov 20217:00 amRNSInterim Results
10th Nov 20217:00 amRNSNotice of Results and Investor Presentation
3rd Nov 202111:03 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.